How a community of affected families transformed into a global research powerhouse accelerating rare disease science
When Patricia Bennett's newborn son was diagnosed with a mysterious condition characterized by weak muscles, frequent infections, and a dangerously enlarged heart, she was told little could be done beyond managing symptoms. The condition was Barth syndrome, an ultra-rare genetic disorder that primarily affects males and threatens survival from infancy. Rather than accept this prognosis, Bennett connected with other families facing the same diagnosis, and in 2000, they transformed their desperation into action by founding the Barth Syndrome Foundation (BSF) 9 .
Caused by mutations in the TAZ gene affecting mitochondrial function
Affects heart, muscles, immune system, and growth
Transformed from support network to research powerhouse
What began as a small support network has evolved into a global research powerhouse that is reshaping the landscape of rare disease science. This is the story of how a community of affected families became integral partners in the scientific process, accelerating the pace of discovery from basic genetic understanding to developing the first approved treatment in just twenty-five years.
Barth syndrome is an X-linked genetic disorder caused by mutations in the TAZ gene, which provides instructions for making a protein called tafazzin that is essential to healthy mitochondrial function 2 4 . This defect disrupts the metabolism of cardiolipin, a special type of fat that forms a critical component of the inner mitochondrial membrane 3 .
At the molecular level, the tafazzin protein functions as a phospholipid-lysophospholipid transacylase - an enzyme that helps maintain the proper structure of cardiolipin 2 . Cardiolipin is not just any lipid; it's essential for the organization of mitochondrial energy production, playing critical roles in the electron transport chain and the formation of ATP, the cell's primary energy currency 4 .
When tafazzin is defective, the body produces less cardiolipin and accumulates a harmful intermediate called monolysocardiolipin (MLCL) 3 . This imbalance disrupts mitochondrial architecture and function, creating an energy crisis particularly affecting tissues with high energy demands - like the heart and skeletal muscles 4 .
| Organ System | Manifestations | Prevalence |
|---|---|---|
| Cardiovascular | Cardiomyopathy, left ventricular non-compaction, arrhythmias | ~90% of patients 4 |
| Immunological | Neutropenia, recurrent infections, susceptibility to sepsis | ~80% of patients 2 |
| Muscular | Hypotonia, muscle weakness, exercise intolerance | Nearly universal 7 |
| Growth | Growth delay, failure to thrive in childhood | ~80% of patients 2 |
| Metabolic | 3-methylglutaconic aciduria, lactic acidosis | >95% when tested 2 |
Before BSF's establishment, Barth syndrome research was fragmented, with few scientists dedicated to studying this ultra-rare condition. The foundation implemented a strategic three-pronged approach to accelerate progress 8 9 :
Supporting projects across basic, translational, and clinical science
Establishing biobanks and disease models for researchers
Connecting academia, industry, and government stakeholders
This strategy transformed Barth syndrome from a little-known condition to a model system for studying mitochondrial biology. The foundation's grant program, launched in 2002, has supported projects spanning from the detailed molecular characterization of tafazzin function to the development of animal models that recapitulate the human disease 8 .
Unlike traditional research pathways driven solely by scientific curiosity, BSF has ensured that patient experience guides investigation. Through careful documentation of the lived experience of Barth syndrome, the foundation has highlighted quality of life issues that require urgent attention 7 .
Studies supported by BSF have revealed that fatigue and muscle weakness significantly impair school performance, social functioning, and overall quality of life 7 . This understanding has helped shape research priorities to address not just longevity but daily functioning, ensuring that new therapies target the symptoms that matter most to patients and families.
Years of Research
Research Projects Funded
Scientific Publications
FDA Approved Treatment
In 2025, a groundbreaking study led by researchers at The Hospital for Sick Children (SickKids) in Toronto revealed a promising new therapeutic target for Barth syndrome - the previously uncharacterized gene ABHD18 3 . The international collaboration, supported by BSF, aimed to find genes that could modify the effects of TAZ mutations.
"ABHD18 was initially an uncharacterized gene with no described function. After a number of experiments and with the help of collaborators, we discovered that ABHD18 encodes a key regulator of cardiolipin metabolism"
The research team employed a sophisticated multi-step methodology:
| Experimental Model | Intervention | Key Outcome Measures | Results |
|---|---|---|---|
| Patient-derived cells | ABHD18 blockade with ABD646 | MLCL levels, mitochondrial function | Reduced MLCL, improved energy production |
| Zebrafish TAZ model | ABHD18 blockade with ABD646 | Heart structure and function | Improved heart muscle function, reversal of elongation |
| Cellular models | Genetic inhibition of ABHD18 | Cardiolipin profile | Restoration of normal cardiolipin species |
This discovery represents a paradigm shift in therapeutic strategy. As Dr. Moffat explained, "Rather than attempting to repair the faulty TAFAZZIN gene directly, we focused on this secondary gene that amplifies the damage when TAFAZZIN is missing" 3 . This approach offers a potentially easier path to treatment, as targeting a single suppression gene may correct the downstream consequences of multiple different TAZ mutations.
The progress in understanding and treating Barth syndrome has relied on a specialized set of research tools and model systems, many developed or supported by BSF.
| Research Tool | Function/Application | Examples from Literature |
|---|---|---|
| TAZ-deficient cell lines | Study molecular mechanisms of cardiolipin deficiency | HL-60 and U937 myeloid cells with TAZ shRNA |
| Animal models | In vivo study of disease progression and treatment | Zebrafish models with TAZ variations 3 |
| Cardiolipin analysis | Quantify CL and MLCL levels for diagnosis and monitoring | HPLC-MS for CL/MLCL ratio measurement |
| Genetic tools | Manipulate gene expression to study function | TAZ-specific shRNAs for knock-down studies |
| Patient registries | Clinical and natural history data collection | BSF-maintained database of patients and mutations 8 |
These tools have enabled researchers to dissect the complex pathophysiology of Barth syndrome at multiple levels, from molecular interactions to whole-organism physiology. The HL-60 myeloid progenitor cell model, for instance, has been instrumental in understanding why Barth syndrome patients develop neutropenia. Research using this model revealed that TAZ deficiency causes accelerated apoptosis (programmed cell death) in myeloid cells through mitochondrial membrane potential dissipation and caspase-3 activation .
In September 2025, the Barth syndrome community celebrated a historic milestone: the FDA accelerated approval of FORZINITY™ (elamipretide), developed by Stealth BioTherapeutics 5 . This marked the first approved treatment specifically for Barth syndrome and represented the culmination of years of research supported by BSF.
Elamipretide is a mitochondria-targeting tetrapeptide that associates with cardiolipin in the inner mitochondrial membrane 4 . By interacting with cardiolipin, elamipretide helps stabilize mitochondrial structure and function, improving energy production and reducing oxidative stress 4 .
The approval was based on data from the TAZPOWER clinical trial, which demonstrated improvements in knee extensor muscle strength - a key measure of physical function for patients who often struggle with debilitating muscle weakness 5 . The most common side effects were injection site reactions, which could be managed with standard treatments 5 .
While the approval of elamipretide represents tremendous progress, important challenges remain. The current approval is limited to patients weighing at least 30 kilograms (approximately 66 pounds), excluding many younger children 5 .
"While we celebrate this critical milestone, we are deeply aware that only half of our patients survive long enough to weigh the 30 kilograms they must in order to be eligible for this treatment now"
Correcting the underlying TAZ mutation for a potential one-time treatment
Developing oral medications targeting different aspects of the disease pathway
Addressing multiple symptoms simultaneously for comprehensive care
The journey of the Barth Syndrome Foundation from a small group of concerned families to an integral partner in scientific discovery offers a blueprint for rare disease research. By fostering collaboration between patients, families, researchers, and clinicians, BSF has dramatically accelerated the pace of progress - from genetic characterization to approved treatment in just over two decades.
What began as a desperate search for answers has transformed into a robust scientific ecosystem that continues to drive innovation.
The foundation's story demonstrates that with strategic vision, persistent advocacy, and meaningful collaboration, even the rarest conditions can attract serious scientific attention.
As research continues to unravel the complexities of Barth syndrome, each discovery not only brings hope to affected families but also deepens our understanding of fundamental biological processes - reminding us that when science and patient passion converge, extraordinary progress is possible.
References will be populated here